ASCO 2022 Conference Coverage


 

Lecture Summary - ASCO 2022 Targeting HER2 Mutation-Positive Advanced Biliary Tract Cancers With Neratinib: Final Results From the Phase 2 SUMMIT Basket Trial

16 views
June 15, 2022
Comments 0
Login to view comments. Click here to Login